Fractyl Health, Inc.
GUTSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 19, 2026 | Craig-Hallum | $5.00(+245%) | $1.45 | TheFly | |
| Jan 29, 2026 | Morgan Stanley | $2.00(+242%) | $0.58 | TheFly | |
| Dec 19, 2025 | Canaccord Genuity | Whitney Ijem | $8.00(+254%) | $2.26 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Buy | Oct 20, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 24, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 26, 2026 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Jan 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 2, 2025 |
| Canaccord Genuity | maintain | Buy | Nov 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 26, 2025 |
| Canaccord Genuity | maintain | Buy | Aug 14, 2025 |
| Morgan Stanley | maintain | Overweight | Feb 3, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-1.59| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-1.92 | $-1.62 | — | — |
| May 13, 2026 | $-0.13 | $-0.17 | — | — |
| Mar 24, 2026 | $-2.04 | $-2.28 | — | — |
| Nov 12, 2025 | $-0.71 | $-4.08 | — | — |
| Aug 13, 2025 | $-4.20 | $-4.44 | — | — |
| May 12, 2025 | $-0.47 | $-5.40 | — | — |
| Apr 7, 2025 | $-0.52 | $-5.28 | $3.0K | $10.0K |
| Nov 13, 2024 | $-5.76 | $-6.00 | $14.0K | $10.0K |
News
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the third quarter 2026 and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET.
BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions to its U.S. patent portfolio that strengthen the intellectual property foundation for investigational Revita® as the Company advances toward a planned U.S. Food and Drug Administration (FDA) De Novo marketing submission for post…
Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS…
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash …
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, …
NEW YORK--(BUSINESS WIRE)---- $GUTS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("“Fractyl” or the “Company”) (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and …
Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About? On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - …
Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts
New class action for Fractyl (GUTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/20/2026
Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days. Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy da…
Fractyl Health (NASDAQ: GUTS) reported six-month top-line results from its ongoing pivotal REMAIN-1 study evaluating its investigational Revita procedure for maintaining weight loss after patients discontinue GLP-1 obesity medicines. The randomized, double-blind, sham-controlled study enrolled adults with obesity who had not previously received GLP-1 treatment. Participants first received tirzepatide during a run-in period, losing an average
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - …
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - …
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham
BENSALEM TOWNSHIP, Pa., Oct. 15, 2026 /PRNewswire/ -- The Law Offices of Howard G.
New class action for Fractyl (GUTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/20/2026
Allegations focus on two public offerings in August and September 2025 that allegedly raised approximately $76.7 million in net proceeds while GUTS shares traded at prices allegedly inflated by the Company's interim Revita data. NEW YORK, Oct. 15, 2026 /PRNewswire/ -- SueWallSt alerts investors in Fractyl Health, Inc. (NASDAQ: GUTS) of a pending securities class action covering purchases between January 13, 2025 and January 29, 2026.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 a…